Association between patient tumour characteristics and five-year survival in Nigerian patients with breast cancer.

近年来研究发现多种伴随基因异常是影响表皮生长因子受体（EGFR）酪氨酸激酶抑制剂（TKI）治疗敏感性的重要因素。其中，TP53 突变是 EGFR ...

Diagnosis requires a tissue biopsy for histopathologic and immunohistochemistry evaluation. Testing for alterations using non-small cell lung cancer (NSCLC) tumor tissue requires acquisition of a ...

"Clinicians performing tumor biopsy need to ensure that there’s adequate tissue for both diagnosis and NGS testing. Having immediate pathology review of biopsy specimens in the operating room can ...

The National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology, American Society of Clinical Oncology (ASCO) and European Society for Medical Oncology (ESMO) guidelines all ...

The FINANCIAL — Insights from experts working on-the-ground in lung cancer, compiled by Boehringer Ingelheim, shed light on challenges faced by patients with advanced stage adenocarcinoma, a type of ...

Oct. 7, 2005 — The U.S. Food and Drug Administration (FDA) has approved an assay for the detection of epidermal growth factor receptor mutations in patients with non-small cell lung cancer; a D-dimer ...

The results published in the Journal of Thoracic Oncology found that the response rate to tyrosine kinase inhibitor therapy was significantly higher in classic vs rare EGFR mutations. Certain rare ...

To guide clinical care for patients with MPLCs, it’s important to identify the possibility of discordant EGFR status in individual tumors. EGFR mutations occur independently in patients with ...